Post-Traumatic Thromboembolism Fondaparinux, Filters and the Future M. Margaret Knudson, MD.

Slides:



Advertisements
Similar presentations
Venous Thromboembolism: Risk Assessment and Prophylaxis
Advertisements

Controversies in the management of Pulmonary Embolism
Unique Challenges in MPNs 2012 Bay Area MPN Patient Symposium Laura C. Michaelis, MD Loyola University Medical Center.
LHD Logo Venous Thromboembolism Reducing the Risk DATE.
Deep venous thrombosis and pulmonary embolism in pregnancy Petr Krepelka, 2013.
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
Prevention of Pulmonary Embolism in high risk trauma patients
Paper Reading Int. 林泰祺.
VTE in abdominal-pelvic surgery patients
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous thromboembolism –
Venous Thromboembolism
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients.
Ch 17. Systemic complications DEEP VENOUS THROMBOSIS.
VTE Prophylaxis Alert to providers and nursing Go live June 24, 2014.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
DVT: Symptoms and work-up Sean Stoneking. DVT Epidemilogy Approximately 600,0000 new cases of DVT each year 50% in hospitalized patients or nursing home.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Total Joint Replacement
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Postoperative venous thromboembolic disease prevention in the neurosurgery population Ahmad Khaldi, M.D. 1 Michael Wall, PharmD 2 T.C. Origitano, M.D.,
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
ARIXTRA® (fondaparinux sodium) in the prevention of venous thromboembolism after hip-fracture surgery BI Eriksson, KA Bauer, MR Lassen, and AGG Turpie.
Venous Thromboembolism
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Preoperative Management of Hypoxic Patients
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.
IVC filters what you need to know Sam Chakraverty Consultant Radiologist Ninewells Hospital Dundee, Scotland.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Risk Assessment for VTE. Which of the following best describes you?
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after major knee surgery KA Bauer, BI Eriksson,
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, Pharmacy, CCE Confidential:
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism 1 (RECORD 1 ) Journal Club General Surgery Rotation.
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,
Case 2: IVC Filters 44 y/o male “preaching pastor” 10/23Generalized seizure Large AVM 2/12Embolization, left frontal craniotomy and resection c/b right.
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,
Venous Thromboembolic (VTE) Prophylaxis in Pediatric Trauma Patients Bowe.
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Outpatient DVT assessment & treatment Daniel Gilada.
Prandoni et al NEJM 375;16 October 20, 2016
By: Dr. Nalaka Gunawansa
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Thromboprophylaxis after Hip Replacement Surgery
Optional IVC Filters: Indications for Placement and Retrieval
The use of Tranexamic Acid to reduce blood loss in paediatric burns: Our institute’s experience Dr Steven Cook, Mr Bernard Carney, Dr  Michelle  Lodge,
Owen N. Johnson, MD, David L
Roger A. Orsini, M.D., Bruce E. Jarrell, M.D. 
Thrombophilia in pregnancy: Whom to screen, when to treat
Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.
Presentation transcript:

Post-Traumatic Thromboembolism Fondaparinux, Filters and the Future M. Margaret Knudson, MD

Historical Perspectives “ A study of protocols of 9,882 postmortem exams including death from injury…in the traumatic group embolisms were found in 61 cases(3.8%) and in the non-traumatic group in 222 cases (2.6%). Statistically, this appears to be a significant difference.” J.S. McCartney, 1934

Historical Perspectives 124 trauma patients: venograms Fracture patients: 35% venous thrombosis Thrombus found within 24 hours of injury Both injured/uninjured extremity 2/3rds with DVT-asymptomatic Freeark et al, 1967

INCIDENCE: OCCULT DVT 349 injured patients: screening venography* None receiving prophylaxis Proximal DVT rate: 18% PE rate: 2% (43% mortality!!) *Geerts et al, NEJM 1994

Incidence of Occult PE after Trauma 90 consecutive patients; ISS> 9 Asymptomatic; no DVT Chest CT: between 3-7 days 22 had clot on CT; 4 were major! 30% were receiving prophylaxis Schultz et al J Trauma 2004

THROMBOEMBOLISM AFTER TRAUMA AN ANALYSIS OF 1602 EPISODES FROM THE ACS NATIONAL TRAUMA DATA BANK Annals of Surgery 2004 M. Margaret Knudson MD Danagra G. Ikossi MD Linda Khaw BA Diane Morabito RN, MPH Larisa S. Speetzen BA The University of California, San Francisco

VTE RISK FACTOR ANALYSIS Hypotheses: Clinical incidence of VTE - relatively low Patients who would benefit from VTE prophylaxis could be clearly identified

METHODS Data source: NTDB ( ) Data analysis: - Demographics - Nature/severity of injuries - Complications/outcomes Survey: participating trauma centers - VTE risk factors/protocols

RESULTS 450,375 patients included 84% blunt injuries 31% ISS> pts: DVT (0.36%) 522 pts: PE (0.13%) 82 pts: both DVT/PE PE mortality: 18.7%

Risk Factor *Odds Ratio Shock on admission (BP < 90 mHg)1.95 Age > 40 yrs.2.29 RISK FACTOR ANALYSIS Head injury (AIS > 3)2.59 Pelvic fracture2.93 p <.0001 for all factors * Greenfield 1997, 2000; Knudson 1994, 1996 Lower extremity fracture3.16 Spinal cord injury with paralysis3.39

Risk FactorOdds Ratio Ventilator days > Venous injury7.93 RISK FACTOR ANALYSIS (CONT’) p <.0001 for all factors Major surgical procedure4.32

Risk FactorOdds Ratio p  for all factors MULTIVARIATE ANALYSIS Ventilator days > Venous injury3.56 Age  40 years 2.01 Lower extremity fracture (AIS  3) 1.92 Major operative procedure1.53 Head injury (AIS  3) 1.24

VENA CAVA FILTERS Procedure code: “IVC plication” 3,883 patients 86%: prophylaxis (no VTE) PE rate in filter group: 4.7% 410 patients: no risk factors Permanent IVC filters

SURVEY RESULTS Majority: identified risk factors for VTE 50%: VTE protocol in place Preferred prophylaxis: LMWH 16%: VCF-heparin contraindicated

CONCLUSIONS Clinically significant VTE rates: low 90% VTE pts. have at least 1 risk factor VTE risk- varies with each factor Role of IVC filters: re-examined

STUDY LIMITATIONS Level II recommendations Quality of data: variable Type II error: spinal cord injuries Risk factors: missed 10% pts with VTE Limited data: pre-existing risk factors Unable to link prophylaxis with VTE

PROPOSED ALGORITHM Injured Patient High Risk Factor High Risk Factor (OR for VTE = 2-3) (OR for VTE = 2-3) Age ≥ 40 Age ≥ 40 Pelvic fx Pelvic fx Lower extremity fx Lower extremity fx Shock Shock Spinal cord injury Spinal cord injury Head trauma (AIS ≥ 3) Head trauma (AIS ≥ 3) Contraindication for heparin? No LMWH* Mechanicalcompression *Prophylactic dose Yes VERY High Risk Factor VERY High Risk Factor (OR for VTE = 4-10) (OR for VTE = 4-10) Major operative procedure Major operative procedure Venous injury Venous injury Ventilator days > 3 Ventilator days > 3 2 or more high risk factors 2 or more high risk factors Contraindication for heparin? LMWH* and mechanicalcompression NoYes Mechanicalcompression and serial CFD OR temporary IVC filter

Practice Patterns VTE Prophylaxis in Trauma 315 patients: 11% VTE Early prophylaxis: 4% risk Prophylaxis after 4 days: 3 times greater!

Fondaparinux Synthetic pentasaccharide; non-heparin Selective AT binding: neutralizes Xa 300 times innate AT III activity

FONDAPARINUX More effective than enoxaparin: ortho Less bleeding/lower mortality: acute MI Once daily dosing No heparin; NO HIT Turpie NEJM 2001; Yusuf NEJM 2006

Fondaparinux for the Prevention of Venous Thromboembolism in High- Risk Trauma Patients J.P. Lu, MD and MM Knudson U. Of California, San Francisco

Study Objectives To evaluate the efficacy and safety of fondaparinux for DVT prophylaxis in trauma patients To implement a VTE prevention protocol based on stratified risk factors To measure Fondaparinux anti Xa activity in trauma patients

Hypotheses VTE rate would be less than 5% in high-risk trauma patients with Fondaparinux Fondaparinux: no increased bleeding risk Anti-Xa activity would be therapeutic

Methods Subjects: consecutive admissions-6 months Inclusion criteria: – Age >=18 – Risk factor for VTE – Anticipated hospital stay >= 5 days Exclusion criteria: – Prisoners – Pregnant women

Risk assessment

Methods Study period: 1-21 days Ultrasound surveillance on admission and then weekly Fondaparinux for DVT prophylaxis if patient had no contraindication; goal: <36hr Anti Xa activity measured at third or fourth dose

Results: demographics Patients who received fondaparinux=81 Age (yrs)43.1 (+/- 19.3) Male sex60 (74%) Blunt Injury51 (63%) Mean ISS18 (+/- 10.1)

Results: incidence of DVT n = 81 n = 6

Results: adverse events 13 (16%) had decrease in hematocrit No transfusions related to the drug No other major AEs identified

Results: anti Xa activity

Summary Fondaparinux: safe and effective in trauma VTE protocol prospectively applied: successfully identified patients at risk Further multi-center studies are warranted J Amer College of Surgeons 2009

Factor VIIa: A New Threat? Empiric administration to bleeding patients Produces hypercoagulable state early Late risk of thromboembolism??? Early data: small but not significant risk

Military experience: rFVII and DVT 615 patients: JTTR Retrospective review-clinical incidence Overall DVT rate: 7.5%; PE rate 3.8% Massive Transfusions: 13% Massive transfusions and rFVII: 18% Prospective study pending Have Sonosite will scan!!!

Trauma Transfusions and Recombinant FVIIa: An Analysis of 380 MM Knudson, MJ Cohen, R Reidy, S Jaeger, P Bacchetti, J Chengshi, CE Wade, JB Holcomb A WTA Multi-Center Studies Group Initiative

Thrombotic Complications EventNumber / % total survivors DVT 26 / 9.9% PE 6 / 2.3% Acute MI 12 / 4.6% Stroke 3 / 1.1% Knudson, JACS 2011

Filter Fever!

Prophylactic Vena Cava Filters? Problems: - Recurrent PE: 3% - No protection against DVT - 10%: caval thrombosis - permanence: leg edema - migration/IVC perforation - timing: 6% PE within 24 hours

Retrievable Filters: “NOT” May be retrieved within 5 days May be left in place: 30 days? Solution for high risk patients? Leads to 3-fold increase use AAST study: >400 patients Only 22% were retrieved! $100,000/ PE prevented Antevil J Trauma 2006 Karmy-Jones J Trauma 2007

POC Coagulation Monitoring Thromb- elastograph (Haemoscope Corp.) Sonoclot (Sienco Inc.) 1 ACT 2 Clot Rate 3 Platelet Function

TEG Monitoring of Enoxaparin Standard prophylactic doses are inadequate in some patients: anti-Xa levels TEG-based dosing decreased DVT Prospective multicenter study Malowski J Trauma 2010; Van J Trauma 2009

Protein C: The Unifying Theory Trauma patients with shock Hypocoagulable state Protein C gets activated: depleted Later become hypercoagulable Low protein C: develop VTE Brohi/Cohen: Annals of Surgery 2006

3738 POST-TRAUMATIC PULMONARY EMBOLI A NEW LOOK AT AN OLD DISEASE M.M.Knudson, D. Gomez, B.Haas, MJ Cohen, AB Nathens U. California San Francisco, U. Toronto

Historical Perspective: Pulmonary Emboli Recognized post-injury complication: 1934* Mortality rates: 25-50% Clinical presentation: acute hypoxia, collapse Diagnostic study: autopsy *McCartney, Am J Pathology

Current Perspective: PE “Potentially preventable” complication Clinical Presentation: unexplained drop Pa0 2 Often incidental finding: multidector CT scan Quality indicator: CMS, JACHO, AHRQ

Purpose To describe the current incidence of pulmonary embolism following trauma in the United States To determine the PE-attributable mortality

Major Hypotheses 1. Risk factors for PE-different from DVT 2. PE-incidence rates are increasing 3. PE-attributable mortality is decreasing

Methods ACS/NTDB Adult patients: Level I/II centers* Current version: Historical comparison: (version 1) Comparison: centers contributing to both Hierarchical logistic regression models: risk factors, mortality *(centers reporting at least one complication)

Results: Current NTDB Cohort 888,652 Patients; 326 Trauma Centers Overall mortality: 1.8% 9,398 episodes: DVT (1.06%) 3,738 episodes: PE (0.42%) Only 20% with PE had DVT reported

Risk Factor Analysis Risk FactorDVT (9,398); OR (95% CI)PE (3,738); OR (95% CI) Severe TBI1.34 ( )*0.87 ( ) Ventilator Days >35.31 ( )*3.81 ( ) Severe Chest Injury (AIS>3)1.07 ( )1.42 ( )* Lower Ext. Fracture (AIS>3)1.53 ( )1.81 ( ) Pelvic Fracture1.32 ( )1.19 ( ) Spine Injury (AIS>4)1.58 ( )1.91 ( ) Shock (SBP<90)1.23 ( )1.19 ( ) Knudson, et al., Annals of Surgery, 2004

Results: IVC Filters 16,809 patients: 1.9% of total population 13,201: Prophylactic Center clustering: 0%-10.6%

Discussion: Potential Explanation 1. True increased incidence of PE 2. Better reporting in NTDB/ NTDS 3. “Sicker” patients in current cohort 4. Failure of VTE prophylactic measures* 5. Improved methods of detection*

Uncoupling DVT and PE Severely Injured Patient Shock Coagulopathy Protein C Depletion? Hypercoagulable State TBIStasis FracturesVenous Injury Chest InjuryInflammation DVTPE

PE rates versus Prophylactic IVC filters Prophylactic IVC FiltersPE rates 0.60% 0.50% 0.40% 0.30% 0.20% 0.10% 0.00% Historical Current 0.49% 0.21% 1.6% 1.4% 1.2% 1.0% 0.80% 0.60% 0.40% 0.20% 0.00% Historical Current 1.5% 0.75%

Conclusions PE: increasingly recognized post injury PE: decreased attributable mortality PE: may develop de novo PE: chest trauma/inflammation PE: may not be prevented by filters Perivascular Hemorrhage Pulm. Artery with Thrombus

MULTIPLE TRANSFUSIONS SEVERE INJURIES PARALYSISIMMOBILIZATION VENOUS TRAUMA FRACTURES STASIS ENDOTHELIAL DAMAGE HYPERCOAGULABILITY Knudson’s Trauma Triad Knudson, et al., J Trauma, 1994

Knudson’sTrauma Square Knudson’s Trauma Square MULTIPLE TRANSFUSIONS SEVERE INJURIES VENOUS TRAUMA FRACTURES CHEST TRAUMA PARALYSISIMMOBILIZATION STASIS ENDOTHELIAL DAMAGE INFLAMMATION HYPERCOAGULABILITY